Altasciences’ Proactive Drug Development Solution—Small Molecules

The process from lead molecule identification to completion of a first‑in‑human trial can be long and complicated. But with Altasciences’ Proactive Drug Development solution, your timelines can be reduced by up to 40%. Your entire program will be managed by one organization and overseen by a single, cross-functional program manager to quickly and seamlessly advance your molecule from preclinical testing to first‑in‑human clinical trials, and beyond—helping you get your medicines to the people who need them, faster.

Learn more by downloading our eBook.

 

Drug Discovery World: Space to Innovate—Where Are Biotech's Top Expansions?

How is Partnering With Altasciences for Your First-in-Human Clinical Trials Different?

Advancing your molecule to first-in-human (FIH) clinical trials is a major milestone in your drug development program. Altasciences is here to help you get there, conduct your study, and provide you with a full range of complementary services.

  • Regulatory Expertise: Our regulatory advisors have extensive experience navigating complex regulatory processes, ensuring your IND and CTA applications are submitted and processed swiftly and efficiently.
  • Scientific and Operational Expertise: You can trust our team to deliver high-quality, customized solutions for your clinical trial needs.
  • Pharmaceutical Manufacturing: We offer a wide range of manufacturing services to support your preclinical and clinical trials.
  • Bioanalysis: With over 260 highly trained specialists and a capacity of over 60K study samples per month, Altasciences has the capacity to process your data quickly.
  • Project Management: A single, dedicated project manager, along with a proprietary information-sharing database, means you only have to Tell Us Once™. Learn more about Altasciences' FIH solutions.

 

Characterization of Normal Skin Thickness For Various Body Regions, Ages, and Genders of Yucatan Miniature Swine

Miniature Swine Model of Atopic Dermatitis—Assessment of In Vivo and In Vitro Activity of Recombinant Porcine Interleukin-4 and Interleukin-13

Why Use Miniature Swine in Dermal Research?

Geometric Determinants of Full-Thickness Wound Healing in Adult Male Yucatan Miniature Swine

Development of a Model of Dermal Inflammation and Irritation (Urticaria) in Miniature Swine

Dermal Toxicology Application Area Changes as Compared to a Theoretical Total Surface Area of Hanford Miniature Swine Over 18 Weeks

Acute Dermal Irritation Response in White Sinclair and Hanford Miniature Swine

Subscribe to